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Abstract
Introduction: Idiopathic Pulmonary Fibrosis (IPF) is a progressive, incurable fibrotic interstitial lung disease with a prognosis
worse than many cancers. Its pathogenesis is poorly understood. Activated platelets can release pro-fibrotic mediators that
have the potential to contribute to lung fibrosis. We determine platelet reactivity in subjects with IPF compared to age-
matched controls.
Methods: Whole blood flow cytometry was used to measure platelet-monocyte aggregate formation, platelet P-selectin
expression and platelet fibrinogen binding at basal levels and following stimulation with platelet agonists. A plasma swap
approach was used to assess the effect of IPF plasma on control platelets.
Results: Subjects with IPF showed greater platelet reactivity than controls. Platelet P-selectin expression was significantly
greater in IPF patients than controls following stimulation with 0.1 mM ADP (1.9% positive 60.5 (mean 6 SEM) versus
0.7%60.1; p = 0.03), 1 mM ADP (9.8%61.3 versus 3.3%60.8; p,0.01) and 10 mM ADP (41.3%64.2 versus 22.5%62.6; p,
0.01). Platelet fibrinogen binding was also increased, and platelet activation resulted in increased platelet-monocyte
aggregate formation in IPF patients. Re-suspension of control platelets in plasma taken from subjects with IPF resulted in
increased platelet activation compared to control plasma.
Conclusions: IPF patients exhibit increased platelet reactivity compared with controls. This hyperactivity may result from the
plasma environment since control platelets exhibit increased activation when exposed to IPF plasma.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is the most common fibrotic
interstitial lung disease and has a prognosis worse than many
cancers [1]. Despite the significant morbidity and mortality
associated with IPF its pathogenesis remains poorly understood
and there is no curative treatment [2].
Epidemiological studies have demonstrated an association
between IPF and vascular diseases including cardiovascular
disease and venous thromboembolism [3,4]. Local imbalance in
the coagulation system has been demonstrated within the alveoli of
IPF patients [5,6] but the systemic vascular effects remain
unexplained. Therapies targeting the coagulation cascade have
been investigated in IPF, but a large randomised controlled trial of
the vitamin K antagonist warfarin was stopped early because of
increased mortality associated with the intervention [7]. This
demonstrates that selectively targeting the coagulation system is
ineffective and potentially harmful in IPF and suggests an
alternative pathway may be responsible for the observed link
between fibrosis and vascular disease.
Blood platelets play a central role in thrombosis through rapid
activation and aggregation at sites of vascular injury. Transient
activation of platelets also induces pro-inflammatory and pro-
fibrotic effects [8] through the release of potent vasoactive
mediators, inflammatory cytokines and pro-fibrotic factors from
dense and a-granules. The role of platelets in lung disease is
unclear, although increased platelet activation has been demon-
strated in adult respiratory distress syndrome (ARDS) [8] and
chronic obstructive pulmonary disease (COPD) [9]. While the role
of platelets in IPF is unknown, platelet trapping in the lungs of
mice following intravenous bleomycin administration strongly
correlated with subsequent collagen deposition, suggesting a role
in fibrogenesis in this animal model [10].
In the present study we measured markers of platelet activation
in IPF patients under basal conditions and following stimulation
with platelet agonists and investigated the effect of plasma from
IPF patients on platelet activation. Our data demonstrate that IPF
is associated with platelet hyperactivity that may be caused by the
plasma environment.
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Methods
Patient Selection
Patients with a diagnosis of idiopathic pulmonary fibrosis
according to ATS/ERS criteria [11] were recruited from the
interstitial lung disease clinic at a large teaching hospital. Age and
sex matched controls without interstitial lung disease were
attending out-patient clinics or were stable in-patients awaiting
discharge. All patients were clinically stable and free from
exacerbation or signs of infection at the time of sampling. A total
of 20 IPF patients and 19 controls were recruited (table 1). Platelet
activation and reactivity was assessed in 13 IPF patients and 12
controls giving a power of 0.8 with a of 0.05 to detect an absolute
5% difference in platelet-monocyte aggregate formation following
stimulation with 1 mM ADP. The effects of IPF plasma on platelet
activation were studied in a further 7 IPF patients and 7 controls.
Additional information on the baseline characteristics of the
participants is available as a data supplement (table S1 and S2 in
file S1).
Ethics Statement
Written informed consent was obtained from all participants
and the study was approved by the Hull and East Riding Local
Research Ethics Committee (LREC ref 08/H1304/54).
Blood sampling and flow cytometric analysis of platelets
Venous blood was collected using a 21G butterfly needle and
vacutainer system (Becton Dickinson Vacutainer Systems, UK).
The first 4.5 mls of blood collected was discarded because
artefactual platelet activation may occur during venepuncture.
Citrated whole blood was added to tubes containing a saturating
concentration of one or more of the following antibodies:
fluorescein isothiocyanate (FITC)-conjugated monoclonal mouse
anti-human CD42b (catalogue number 555472, BD Biosciences,
UK); phycoerythrin (PE)-conjugated monoclonal mouse anti-
human CD14 (product code MCA1568PE, AbD Serotec, UK);
PE-conjugated monoclonal mouse anti-human CD62P (product
code 304906, Biolegend, San Diego, California); or FITC-
conjugated polyclonal rabbit anti-human fibrinogen (product code
F0111, Dako, UK). To study the sensitivity of platelets to
activation, some tubes were supplemented with adenosine
diphosphate (ADP) (0.1, 1 and 10 mM) or the protease activated
receptor - 1 (PAR1) agonist TFLLR (1, 5 and 10 mM). Single
colour flow cytometry was used to assess platelet P-selectin
expression and fibrinogen binding. Two-colour flow cytometry
was used to identify the proportion of monocytes forming
aggregates with one or more platelets (dual CD42b/CD14
positive) based on established methods [12].
Effect of IPF Plasma on Control Platelets: Plasma Swap
In order to assess the effect of IPF plasma on control platelets a
plasma swap approach was used. Blood from IPF patients and
Table 1. Baseline characteristics of study participants.
Demographic IPF (%) Controls (%)
Number n = 20 n = 19
Age (mean) 71.2 65.6
Gender
Male 15 (75.0) 12 (63.2)
Female 5 (25.0) 7 (36.8)
Comorbidities
COPD 2 (10.0) 8 (42.1)
Prev. malignancy 2 (10.0) 1 (5.3)
Hypertension 5 (25.0) 3 (15.8)
Diabetes mellitus 1 (5.0) 0 (0)
Ischaemic heart disease 1 (5.0) 0 (0)
TIA 4 (20.0) 0 (0)
Stroke 0 (0) 0 (0)
Atrial fibrillation 1 (5.0) 2 (10.5)
Chronic kidney disease 0 (0) 0 (0)
Smoking Status
Non-smoker 3 (15.0) 8 (42.1)
Ex-smoker 14 (70.0) 8 (42.1)
Current smoker 2 (10.0) 2 (10.5)
Unknown 1 (5.0) 1 (5.3)
Blood Counts – mean (SD)
Haemoglobin (g/dL) 14.2 (1.4) 12.9 (1.9)
White Cell Count (x109/L) 7.4 (1.4) 6.9 (1.8)
Platelets (x109/L) 241.6 (58.5) 267.4 (74.1)
COPD: chronic obstructive pulmonary disease; TIA: transient ischaemic attack. Blood count results were available for 20 IPF patients and 13 controls.
doi:10.1371/journal.pone.0111347.t001
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controls was used for the preparation of platelet-poor plasma.
Washed platelets from control subjects were suspended in
phosphate buffered saline (PBS) and divided into three aliquots.
Plasma from the same donor was added to the first aliquot to form
an autologous control. Plasma collected from a different control
patient was added to the second aliquot to form an allogeneic
control. Plasma from a patient with IPF was added to the third
aliquot. The ratio of platelet suspension to plasma was 1:1 (v/v).
Samples were incubated with PE-conjugated anti-human CD62P
antibody (product code 304906, Biolegend, San Diego, California)
under basal conditions and in the presence of ADP (0.1, 1 and
10 mM) for 20 minutes prior to fixation and flow cytometric
analysis. Additional detail on the methods for assessing the effects
of IPF plasma on control platelets is provided in data supplement
file S1.
Data Analysis
Flow cytometry was performed using a FACS Calibur flow
cytometer (Becton Dickinson, Oxford, UK) and the data were
analysed using CellQuest Pro software (Becton Dickinson, Oxford,
UK). Statistical comparisons of platelet-monocyte aggregate
formation, platelet P-selectin expression and platelet fibrinogen
binding between IPF and controls were performed using unpaired
t-tests. A paired t-test was used to assess the difference in P-selectin
expression between the groups in the plasma swap experiment. A
p value of ,0.05 was considered significant.
Results
Platelet-monocyte aggregate formation
Patients with IPF and controls were matched for age and
gender. When whole blood was stimulated with ADP (1–10 mM)
Figure 1. Platelet-monocyte aggregate formation in IPF patients and controls. A. Scatter plot demonstrating the different cell populations
on whole blood flow cytometry, gated on monocytes. B. Quadrant plot demonstrating platelet-monocyte aggregates in the right upper quadrant. X-
axis (FL1) shows CD42b staining and y-axis (FL2) shows CD14 staining. C. Percentage of monocytes forming aggregates with platelets at basal levels
and in response to the platelet agonists ADP (0.1–10 mM) or TFLLR (1–10 mM). * P#0.01.
doi:10.1371/journal.pone.0111347.g001
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or TFLLR (1–10 mM), subjects with IPF demonstrated signifi-
cantly greater platelet-monocyte aggregate formation compared
with controls (Figure 1 and table S3 in file S1). The percentage of
monocytes with bound platelets was significantly greater in IPF
patients following stimulation with 1 mM ADP (29.4%64.1 (mean
6 SEM) versus 16.1%61.5 in controls; p =,0.01) and 10 mM
ADP (44.8%63.3 versus 32.1%63.5; p = 0.01). Platelet-monocyte
aggregate formation in blood from IPF patients was also
significantly increased following stimulation with 5 mM and
10 mM TFLLR (figure 1) when compared to controls. Under
basal (unstimulated) conditions, blood from IPF patients exhibited
greater platelet-monocyte aggregate formation than controls but
this did not reach statistical significance (18.2%63.9 versus
13.7%61.4; p = 0.3). The calcium-dependent nature of the
interaction between platelets and monocytes was confirmed by
addition of EDTA, which resulted in a marked reduction in
aggregate formation that did not increase in response to agonist
stimulation and did not vary significantly between the groups
(figure 2).
Platelet P-selectin expression and fibrinogen binding
Having established that platelet-monocyte aggregates were
increased in IPF, we next examined other markers of platelet
activation. Consistent with increased platelet-monocyte aggregates
we found that platelet P-selectin expression was elevated in whole
blood from IPF patients compared with controls. Stimulation with
all concentrations of ADP led to greater increases in platelet P-
selectin expression in IPF patients compared with controls (ADP
0.1 mM: 1.9%60.5 positive platelets versus 0.7%60.1; p = 0.03;
ADP 1 mM: 9.8%61.3 versus 3.3%60.8; p =,0.01; ADP
10 mM: 41.3%64.2 versus 22.5%62.6; p=,0.01). Similar
findings were observed following stimulation with TFLLR
(figure 3 and table S4 in file S1). No differences were observed
under basal (unstimulated) conditions.
The percentage of platelets binding fibrinogen was significantly
higher in IPF patients compared with controls following stimula-
tion with 0.1 mM and 1 mM ADP (0.1 mM ADP: 50.3%68.9
versus 17.5%66.1; p=,0.01; 1 mM ADP: 77.9%64.6 versus
56.2%66.5; p=,0.01). There was no significant difference in
fibrinogen binding under basal (unstimulated) conditions
(19.9%66.0 versus 8.7%63.2 respectively; p = 0.13). The increase
in fibrinogen binding in IPF subjects following stimulation with
TFLLR did not reach statistical significance (figure 4 and table S5
in file S1).
The influence of the plasma environment on platelet
function in IPF
We next examined whether the platelet hyperactivity observed
in IPF was caused by a primary platelet defect or the plasma
environment. Re-suspension of washed control platelets in plasma
from IPF subjects led to elevated P-selectin expression when
compared with platelets suspended in autologous control or
allogeneic control plasma. IPF plasma increased P-selectin
expression under both basal conditions (p,0.05) and following
stimulation with ADP at concentrations of 0.1 and 1 mM (P#0.01)
(figure 5 and table S6 in file S1). Further analysis was performed to
confirm the increase in platelet P-selectin expression seen in IPF
plasma. From a baseline taken as the platelet P-selectin expression
in the autologous control group, the increase in platelet P-selectin
expression in the presence of IPF plasma was significantly greater
than the allogeneic control group at basal levels and following
stimulation with all concentrations of ADP (p,0.05).
Discussion
We have demonstrated platelet hyperactivity in patients with
IPF using two mechanistically different agonists (ADP and
TFLLR) and three different markers of platelet activation, namely
Figure 2. Percentage of monocytes forming aggregates with platelets in the presence of 1 mM EDTA under basal conditions and
when stimulated with ADP (0.1–10 mM) or TFLLR (1–10 mM) in subjects with IPF and controls.
doi:10.1371/journal.pone.0111347.g002
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platelet-monocyte aggregate formation, platelet P-selectin expres-
sion, and platelet fibrinogen binding. Increased platelet-monocyte
aggregate formation is a sensitive marker of platelet activation [13]
and demonstrates a functional consequence of the increased
platelet reactivity. These data provide robust evidence of increased
platelet reactivity in IPF.
To explore whether the hyperactivity phenotype in IPF was the
result of an alteration of the platelets or their environment we used
the plasma swap approach, which has been used successfully in
previous studies to examine the role of plasma [14]. Incubation of
washed control platelets in IPF plasma increased platelet activation
as assessed by P-selectin expression both under basal conditions
and after stimulation with ADP. Platelet hyperactivity was not
observed when platelets were incubated with control plasma. This
indicates that the plasma environment in IPF is responsible for the
observed increased platelet reactivity. Further investigation is
required to identify the plasma factor or factors responsible for this
effect.
The two patient groups in this study were well matched in terms
of age and gender. At the time of undertaking the platelet assays
there was no evidence-based disease modifying treatment for IPF
[2] and therefore it was local practice not to treat IPF patients with
immunosuppressant drugs. This is reflected in our cohort with
only 1 IPF patient receiving long term low dose prednisolone. One
patient in the control group was also taking long term low dose
prednisolone as treatment for COPD.
Although not statistically significant, there was a higher
prevalence of cerebrovascular disease in the IPF group. There is
a recognised association between cerebrovascular disease and
platelet activation [15], but repeat analysis of our data following
exclusion of patients with a history of cerebrovascular disease did
not alter our conclusions. The platelet assays used in this study are
not affected by aspirin [16] and reanalysis of the data following
exclusion of patients using antiplatelet therapies did not alter our
conclusions.
It has recently been demonstrated that patients with COPD
have increased levels of circulating platelet-monocyte aggregates
compared to age and smoking status matched controls [9]. The
high prevalence of COPD in our control group may therefore
result in the differences between the groups being underestimated,
Figure 3. Platelet P-selectin expression in IPF patients and controls. A. Representative flow cytometry histogram demonstrating platelet P-
selectin expression under basal (unstimulated) conditions. B. Flow cytometry histogram demonstrating platelet P-selectin expression following
stimulation with 10 mM ADP. C. Percentage of platelets expressing P-selectin at basal levels and in response to the platelet agonists ADP (0.1–10 mM)
or TFLLR (1–10 mM). { P,0.05, * P#0.01.
doi:10.1371/journal.pone.0111347.g003
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adding further support to the significance of the observed
increased platelet reactivity in patients with IPF. The current
smokers in this study were evenly distributed between IPF and
control groups, indicating that the documented increased platelet
activation and surface expression of P-selectin in smokers [17] will
not have influenced our conclusions.
It is recognised that the choice of ex-vivo anticoagulant can
impact platelet-monocyte association. Citrate results in lower
levels of platelet-monocyte aggregates secondary to calcium
chelation [18] whereas heparin-based anticoagulants may activate
platelets through interactions with the platelet integrin aIIbb3 [19].
There is currently no consensus on the optimal anticoagulant for
assessing platelet-monocyte aggregates. To minimise platelet
activation we opted to use sodium citrate, which may have
reduced our ability to detect a significant difference in platelet
activation at basal levels in the present study. Since both groups
were subject to the same conditions the differences observed
between the groups will not have been affected by the choice of
anticoagulant, but caution should be exercised when comparing
our results with those from other studies using different
anticoagulants.
The present study does not establish a temporal relationship
between platelet activation and development of IPF, and in
isolation we cannot conclude whether the observed increased
platelet reactivity is an important phenomenon at the onset of the
disease or represents a secondary response to pulmonary fibrosis.
Although epidemiological studies have reported that the increased
incidence of cardiovascular events and venous thromboembolism
in IPF patients predates the presentation of lung disease [3,4],
caution must be exercised when drawing conclusions regarding
cause and effect. However, it is important to recognise the pro-
fibrotic potential of activated platelets. Platelet degranulation leads
to the release of pro-fibrotic mediators including platelet derived
growth factor (PDGF) [20] and transforming growth factor-beta
(TGF-b) [21], which have been proposed to be key mediators in
the pathogenesis of IPF [22–24]. We suggest that the increased
platelet reactivity in patients with IPF may perpetuate the
pulmonary fibrotic process through platelet sequestration in the
lung and local release of pro-fibrotic mediators. Indeed, lung
retention of platelets has been described in the bleomycin animal
model of pulmonary fibrosis [10].
Therefore, in this small study of platelet activation in IPF we
present clear evidence of increased platelet reactivity in IPF
patients compared to controls and demonstrate that this effect can
be reproduced in control platelets incubated in IPF plasma. This
provides insight into the link between IPF and vascular diseases
Figure 4. Platelet fibrinogen binding in IPF patients and controls. A. Representative flow cytometry histogram demonstrating platelet
fibrinogen binding under basal (unstimulated) conditions. B. Flow cytometry histogram demonstrating platelet fibrinogen binding following
stimulation with 10 mM ADP. C. Percentage of platelets binding fibrinogen at basal levels and in response to the platelet agonists ADP (0.1–10 mM) or
TFLLR (1–10 mM). * P#0.01.
doi:10.1371/journal.pone.0111347.g004
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and we have described a mechanism by which platelet activation
may perpetuate fibrosis. Activation of platelets represents an early
stage in thrombosis and is unaffected by treatment with the
vitamin K antagonist warfarin. The lack of benefit from
anticoagulant therapies in IPF may be because the wrong
component of the thrombotic process has been targeted [7].
Conclusion
We have demonstrated increased platelet reactivity in IPF
patients that is reproducible with diverse agonists and different
markers of platelet activation. The increased activation and
reactivity of control platelets when incubated in IPF plasma
suggests that the abnormal platelet response in IPF is due to the
plasma environment. This is the first report of increased platelet
reactivity in IPF patients providing insight into the relationship
between IPF and vascular disease and highlighting the need for
further investigation of the role of platelets in IPF pathogenesis.
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